J&J COVID-19 Vaccine Rollout Resumes In EU With New Rare Blood Clot Warning

Countries May Impose Age Restrictions

Similarities to AstraZeneca blood clots are clear, but more research needed before any ‘class effect’ conclusions can be drawn.

Janssen Pharmaceutica sign and logo
J&J hopes the EMA's review will reassure people in Europe that the vaccine is safe.

More from Business

More from Scrip